Breast IHC AI is an automated, AI-based decision-support tool that standardizes scoring of HER2, ER, PR, and Ki67 IHC on whole slide images (WSI) in accordance with clinical scoring guidelines. It is seamlessly integrated into the HALO AP® diagnostic digital pathology platform.
Breast IHC AI is For Research Use Only and not intended for clinical diagnostic use.
WSI of resections, excisions, and/or biopsies from primary invasive breast cancer
- HER2: HER2 score, percent HER2 1+, 2+, 3+ cells
- ER and PR: Allred Score; Intensity Score; percent of weak, moderate, and strongly positive cells
- Ki67: Percent of positive cells
- HER2: 4B5; CB11
- ER: EP1; SP1
- PR: PgR636; Pgr A/B: 16+SAN27
- Ki67: MIB1, SP6
Breast IHC AI may be compatible with additional clones. Contact firstname.lastname@example.org for more information.
Breast IHC AI Brochure
Learn more about the automated workflow and benefits of Breast IHC AI.
Development & Validation of an AI-based Workflow for Clinical Scoring of HER2, ER, PR, & Ki67 Immunohistochemistry in Breast Cancer Tissue
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Leica Aperio GT 450 and Hamamatsu NanoZoomer S360
Supported File Formats
SVS, NDPI, NDPIS
Breast IHC AI may be compatible with additional file formats. Contact email@example.com for more information.
Breast IHC AI Brochure
Learn more about the automated workflow and benefits of HALO Breast IHC AI (RUO).
Standardize Biomarker Evaluation
Breast IHC AI allows you to standardize your reporting, reducing variability in the IHC evaluation process.
More Efficient Workflow
By automating time-consuming manual tasks, Breast IHC AI significantly reduces the workload for pathologists and researchers. This efficiency boost allows for faster decisions without compromising accuracy.
Complement Your Expertise
Breast IHC AI serves as an additional tool to aid your analyses. By handling tedious tasks and providing consistent, standardized measurements, it frees you to apply your expertise where it’s needed most, in the interpretation of results to make informed decisions.
Breast IHC AI includes AI-based analysis assays for automated scoring of HER2, ER, PR, and Ki67. Each assay has built-in artifact exclusion, benign epithelial region exclusion, and tumor detection steps to ensure that biomarker analysis is performed accurately and consistently each and every time. Tumor cells are analyzed for expression of HER2, ER, PR, and Ki67 and a comprehensive set of results and markups are generated for each image, including a clinical score and percentage positivity.
Key Output Metrics
Seamless Deployment in HALO AP®
Breast IHC AI is deployed and fully integrated into HALO AP®, the AI-powered, pathologist-driven platform for anatomic pathology workflows from Indica Labs.
Want to Learn More?
Fill out the form below to request a live demo of Breast IHC AI or to learn more about our other clinical solutions.
You can also drop us an email at firstname.lastname@example.org
Accessing Breast IHC AI in our CE-marked case management and viewing platform, HALO AP®, provides end-to-end integration to scanners and LIS | LIMS while providing built in compliance and certifications: CE-IVD, FDA 21 CFR Part 11, ISO 13485:2016, HIPAA, and GDPR.
Breast IHC AI is for Research Use Only and not intended for clinical diagnostic use.
HALO AP® is CE-marked for in-vitro diagnostic use in Europe and the UK. HALO AP is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use.